We are live on ! Find out more
FCMI

Foresite Capital Management III Portfolio holdings

AUM $37.9M
1-Year Est. Return 6.87%
This Fund
S&P 500
This Quarter Est. Return
+60.69%
1 Year Est. Return
-6.87%
3 Year Est. Return
+444.07%
5 Year Est. Return
+547.28%
10 Year Est. Return
–
AUM
$112M
AUM Growth
+$49.7M
Cap. Flow
+$19.7M
Cap. Flow %
17.49%
Top 10 Hldgs %
100%
Holding
11
New
2
Increased
3
Reduced
–
Closed
3

Top Buys

Rank Stock Value
1
ORIC icon
Oric Pharmaceuticals
ORIC
+$15.9M
2
BPMC
Blueprint Medicines
BPMC
+$5.39M
3
EPZM
Epizyme, Inc
EPZM
+$4.97M
4
CBAY
Cymabay Therapeutics
CBAY
+$4.62M
5
MYOK
MyoKardia, Inc. Common Stock
MYOK
+$1.16M

Top Sells

Rank Stock Value
1
IMMU
Immunomedics Inc
IMMU
+$5.39M
2
AERI
Aerie Pharmaceuticals
AERI
+$4.81M
3
BHVN
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
+$2.12M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
MYOK
1
DELISTED
MyoKardia, Inc. Common Stock
MYOK
$38.6M 34.31%
399,360
+13,908
+4% +$1.16M
BPMC
2
DELISTED
Blueprint Medicines
BPMC
$19.5M 17.31%
249,598
+79,698
+47% +$5.39M
ORIC icon
3
Oric Pharmaceuticals
ORIC
$1.22B
$16.8M 14.9%
+496,893
New +$15.9M
EPZM
4
DELISTED
Epizyme, Inc
EPZM
$16M 14.26%
998,278
+284,466
+40% +$4.97M
NTRA icon
5
Natera
NTRA
$36.7B
$10.4M 9.26%
208,768
– –
CBAY
6
DELISTED
Cymabay Therapeutics
CBAY
$5.58M 4.97%
+1,599,958
New +$4.62M
XLRN
7
DELISTED
Acceleron Pharma
XLRN
$4M 3.56%
42,030
– –
KYNB
8
Kyntra Bio
KYNB
$29M
$1.62M 1.44%
1,600
– –
AERI
9
DELISTED
Aerie Pharmaceuticals
AERI
– –
-356,492
Closed -$4.81M
IMMU
10
DELISTED
Immunomedics Inc
IMMU
– –
-400,000
Closed -$5.39M
BHVN
11
DELISTED
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
– –
-62,245
Closed -$2.12M

Similar funds

PIM
Ponoi II Management San Francisco, California $38.3M AUM 32.02% 1-Year Est. Return
KCGDR
Kiron Capital Gestao de Recursos Sao Paulo, Brazil $36.9M AUM 49.85% 1-Year Est. Return
SEM
Spectrum Equity Management San Francisco, California $39.1M AUM 63.69% 1-Year Est. Return
ALFIA
Accel Leaders Fund II Associates Palo Alto, California $36.6M AUM 58.14% 1-Year Est. Return
MCMI
Matrix China Management III Grand Cayman, Cayman Islands $39.3M AUM
LCM
LH Capital Markets New York $39.4M AUM 14.61% 1-Year Est. Return
HLC
Hunt Lane Capital New York $39.6M AUM 58.74% 1-Year Est. Return
KXA
KPCB XV Associates Menlo Park, California $35.8M AUM 57.59% 1-Year Est. Return

Foresite Capital Management III's Q2 2020 Portfolio in Review

As of Q2 2020, Foresite Capital Management III held 11 positions worth $112M, up 79% from $62.8M the previous quarter. Its ten largest holdings account for 100% of the portfolio.

Foresite Capital Management III deployed $19.7M of net new capital in Q2 2020, opening 2 new positions and adding to 3 existing holdings. Its largest new stake was Oric Pharmaceuticals: 496,893 shares worth $16.8M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 84% a quarter earlier.

On the sell side, the most notable exit was Immunomedics Inc, an estimated $5.39M sold.

  • Foresite Capital Management III's largest Q2 2020 buy was Oric Pharmaceuticals: 496,893 shares worth $16.8M.
  • Foresite Capital Management III added most to Blueprint Medicines in Q2 2020, an estimated $5.39M increase.
  • Foresite Capital Management III fully exited Immunomedics Inc in Q2 2020, selling an estimated $5.39M.
  • Foresite Capital Management III's ten largest holdings make up 100% of its $112M portfolio in Q2 2020.
  • Foresite Capital Management III opened 2 new positions and closed 3 in Q2 2020.
  • Foresite Capital Management III's portfolio value rose 79% quarter-over-quarter to $112M.

Based on Foresite Capital Management III's 13F filing for Q2 2020, filed 13 Aug 2020.